Package Leaflet: Information for the Patient
GIOTRIF 40mg film-coated tablets
afatinib
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
GIOTRIF is a medicine that contains the active substance afatinib. It works by blocking the activity of a group of proteins called the ErbB family (including EGFR [Epidermal Growth Factor Receptor or ErbB1], HER2 [ErbB2], ErbB3 and ErbB4). These proteins are involved in the growth and spread of cancer cells, and may be affected by changes (mutations) in the genes that produce them. By blocking the activity of these proteins, this medicine can inhibit the growth and spread of cancer cells.
This medicine is used on its own to treat adult patients with a specific type of lung cancer (non-small cell lung cancer):
Do not take GIOTRIF
Warnings and precautions
Talk to your doctor or pharmacist before you start taking this medicine:
Tell your doctor immediately while taking this medicine:
See also section 4 “Possible side effects”.
Children and adolescents
GIOTRIF is not recommended for use in children and adolescents. Do not give this medicine to children or adolescents under 18 years.
Other medicines and GIOTRIF
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including herbal medicines and medicines obtained without a prescription.
In particular, the following medicines, if taken before GIOTRIF, may increase GIOTRIF levels in the blood and, therefore, the risk of side effects. Therefore, these medicines should be taken as far apart as possible from GIOTRIF. This means leaving a gap of at least 6 hours (for medicines taken twice a day) or 12 hours (for medicines taken once a day) between taking these medicines and GIOTRIF:
The following medicines may decrease the effectiveness of GIOTRIF:
Ask your doctor if you are not sure when to take these medicines.
GIOTRIF may increase the levels of other medicines in the blood, including the following medicines:
Tell your doctor before taking these medicines with GIOTRIF.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
You should avoid becoming pregnant while taking this medicine. If you could become pregnant, you must use effective contraception during treatment and for at least 1 month after taking the last dose of this medicine. This is because there may be a risk of harm to the unborn baby.
If you become pregnant while taking this medicine, tell your doctor immediately. Your doctor will decide with you whether you should continue treatment or not.
You should ask your doctor for advice if you plan to become pregnant after taking the last dose of this medicine, as your body may not have fully eliminated this medicine.
Breast-feeding
You must not breast-feed while taking this medicine, as it may harm your baby.
Driving and using machines
If you experience symptoms related to treatment that affect your vision (e.g. redness and/or irritation of the eye, dry eye, watery eyes, sensitivity to light) or your ability to concentrate and react, it is recommended that you do not drive or use machines until the side effects have resolved (see section 4 Possible side effects).
GIOTRIF contains lactose
This medicine contains a sugar called lactose. If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
Dosage
The recommended dose is 40 mg once a day.
Your doctor may adjust (increase or decrease) your dose based on how well you tolerate this medicine.
When to take GIOTRIF
GIOTRIF should be taken by mouth. If you have problems swallowing the tablet, dissolve it in a glass of water. Do not use other liquids. Put the tablet in the water without crushing it and stir the water from time to time for about 15 minutes until the tablet has broken up into very small particles. Drink the liquid immediately. To make sure you take all of the medicine, fill the glass with water again and drink it.
If you are unable to swallow and have a gastric tube, your doctor may suggest that the medicine be given through the tube.
If you take more GIOTRIF than you should
Contact your doctor or pharmacist immediately. You may experience more intense side effects and your doctor may interrupt treatment and provide supportive treatment.
If you forget to take GIOTRIF
Do not take a double dose (two tablets at the same time instead of one) to make up for a missed dose.
If you stop taking GIOTRIF
Do not stop taking this medicine without talking to your doctor first. It is important that you take this medicine every day, while your doctor prescribes it for you. If you do not take this medicine as prescribed by your doctor, your cancer may start to grow again.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, GIOTRIF can cause side effects, although not everybody gets them.
Tell your doctor immediately if you notice any of the following serious side effects. In some cases, your doctor may need to interrupt treatment and reduce your dose or stop treatment:
Diarrhea that lasts more than 2 days or severe diarrhea can lead to loss of fluids (frequent, may affect up to 1 in 10 patients), low potassium levels in the blood (frequent) and worsening of kidney function (frequent). Diarrhea can be treated. As soon as the first symptoms of diarrhea appear, drink plenty of fluids. Tell your doctor immediately and start antidiarrheal treatment as soon as possible. You should have an antidiarrheal medicine ready before starting treatment with GIOTRIF.
It is important to start treatment for the rash as soon as possible. Tell your doctor as soon as a rash appears. If the treatment for the rash does not work and the rash worsens (e.g. if your skin peels or blisters appear) you should tell your doctor immediately, as your doctor may decide to interrupt your treatment with GIOTRIF. The rash may appear or worsen in areas of the body exposed to the sun. It is recommended to use appropriate clothing and sunscreen as protective measures against the sun.
Eye irritation or inflammation can occur (conjunctivitis/dry eye occurs frequently and keratitis occurs uncommonly). Tell your doctor if you experience sudden onset or worsening of eye symptoms such as eye pain or redness or dry eyes.
If you experience any of these symptoms, tell your doctor as soon as possible.
The following side effects have also been reported:
Very common side effects(may affect more than 1 in 10 patients):
Common side effects(may affect up to 1 in 10 patients):
Uncommon side effects(may affect up to 1 in 100 patients):
Rare side effects(may affect up to 1 in 1,000 patients):
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, pouch and blister after EXP. The expiry date is the last day of the month shown.
Store in the original package to protect from moisture and light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of GIOTRIF
Appearance and Package Contents of the Product
GIOTRIF 30 mg are dark blue, round film-coated tablets. They have the code “T30” engraved on one side and the Boehringer Ingelheim logo on the other.
GIOTRIF film-coated tablets are available in packages containing 1, 2, or 4 single-dose precut blisters. Each blister contains 7 x 1 film-coated tablets and is packaged in an aluminum bag along with a desiccant that should not be swallowed.
Only certain package sizes may be marketed.
Marketing Authorization Holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Manufacturer
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Boehringer Ingelheim France
100-104 Avenue de France
75013 Paris
France
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium Boehringer Ingelheim SComm Tel: +32 2 773 33 11 | Lithuania Boehringer Ingelheim RCV GmbH & Co KG Lithuanian branch Tel: +370 5 2595942 |
Luxembourg Boehringer Ingelheim SComm Tel: +32 2 773 33 11 | |
Czech Republic Boehringer Ingelheim spol. s r.o. Tel: +420 234 655 111 | Hungary Boehringer Ingelheim RCV GmbH & Co KG Hungarian branch Tel: +36 1 299 8900 |
Denmark Boehringer Ingelheim Danmark A/S Tlf: +45 39 15 88 88 | Malta Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 |
Germany Boehringer Ingelheim Pharma GmbH & Co. KG Tel: +49 (0) 800 77 90 900 | Netherlands Boehringer Ingelheim B.V. Tel: +31 (0) 800 22 55 889 |
Estonia Boehringer Ingelheim RCV GmbH & Co KG Estonian branch Tel: +372 612 8000 | Norway Boehringer Ingelheim Norway KS Tlf: +47 66 76 13 00 |
Greece Boehringer Ingelheim Ελλάς Μονοπρόσωπη Α.Ε. Tηλ: +30 2 10 89 06 300 | Austria Boehringer Ingelheim RCV GmbH & Co KG Tel: +43 1 80 105-7870 |
Spain Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00 | Poland Boehringer Ingelheim Sp. z o.o. Tel: +48 22 699 0 699 |
France Boehringer Ingelheim France S.A.S. Tél: +33 3 26 50 45 33 | Portugal Boehringer Ingelheim Portugal, Lda. Tel: +351 21 313 53 00 |
Croatia Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 600 | Romania Boehringer Ingelheim RCV GmbH & Co KG Bucharest branch Tel: +40 21 302 2800 |
Ireland Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 | Slovenia Boehringer Ingelheim RCV GmbH & Co KG Ljubljana branch Tel: +386 1 586 40 00 |
Iceland Vistor hf. Tel: +354 535 7000 | Slovak Republic Boehringer Ingelheim RCV GmbH & Co KG organizational unit Tel: +421 2 5810 1211 |
Italy Boehringer Ingelheim Italia S.p.A. Tel: +39 02 5355 1 | Finland Boehringer Ingelheim Finland Ky Tel: +358 10 3102 800 |
Cyprus Boehringer Ingelheim Ελλάς Μονοπρόσωπη Α.Ε. Tηλ: +30 2 10 89 06 300 | Sweden Boehringer Ingelheim AB Tel: +46 8 721 21 00 |
Latvia Boehringer Ingelheim RCV GmbH & Co KG Latvian branch Tel: +371 67 240 011 | United Kingdom (Northern Ireland) Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 |
Date of the Last Revision of this Leaflet:
Other Sources of Information
Detailed information on this medication is available on the European Medicines Agency website: https://www.ema.europa.eu.